Susan Lee Perlman MD
Movement Disorder, Neurodegenerative, Neurodevelopmental Disabilities
Professor, Neurology, UCLA School of Medicine
Join to View Full Profile
300 Medical Plaza, Suite B 200Los Angeles, CA 90095
Phone+1 310-794-1195
Fax+1 310-794-1195
Dr. Perlman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1976 - 1979
- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1975 - 1976
- Stony Brook University Health Sciences Center School of MedicineClass of 1975
Certifications & Licensure
- CA State Medical License 1976 - 2026
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD)
- Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Start of enrollment: 2007 Dec 01
- Study to Assess the Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia Patients Start of enrollment: 2008 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- A global perspective on research advances and future challenges in Friedreich ataxia.Elisabetta Indelicato, Martin B Delatycki, Jennifer Farmer, Marcondes C França Jr, Susan Perlman
Nature Reviews. Neurology. 2025-04-01 - Content Validity of the Friedreich Ataxia Rating Scale in Patients with Spinocerebellar Ataxia.Michele Potashman, Katja Rudell, Naomi Suminski, Rinchen Doma, Maggie Heinrich
Neurology and Therapy. 2025-04-01 - Spinocerebellar Ataxia Progression Measured with the Patient-Reported Outcome Measure of Ataxia.Anna L Burt, Gilbert L'Italien, Susan L Perlman, Liana S Rosenthal, Sheng-Han Kuo
Movement Disorders. 2025-03-04
Press Mentions
- Skyclarys (Omaveloxolone) Becomes the First FDA-Approved Treatment for Friedreich’s AtaxiaMarch 10th, 2023
- FDA Approves SkyclarysJanuary 3rd, 2023
- Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio ProgressDecember 8th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
